Table 2. Cell surface targets in AML... | American Society of Hematology

Table 2.

Cell surface targets in AML currently under preclinical or clinical study

Target	Monoclonal antibody	ADC	Bispecific antibody	CAR T Cell
CD7				X
CD13	X		X
CD33	X	X¹ NCT02724163	X¹ NCT05077423	X¹ NCT03971799
CD38	X¹ NCT03860844			X
CD44v6	X			X
CD47	X
CD56		X		X
CD70	X	X		X
CD74		X
CD117		X
CD123	X	X¹ NCT05320380	X	X¹ NCT04318678, NCT04678336
CD135 (FLT3)			X	X¹ NCT03904069
Mesothelin		X	X	X
Folate receptor α (FOLR1)		X²		X
PRAME				X³
WT1				X³
HA-1				X^1,3 NCT03326921
NKG2DL				X
IL1RAP				X
CLL-1 (CLEC12A)		X	X	X

Target	Monoclonal antibody	ADC	Bispecific antibody	CAR T Cell
CD7				X
CD13	X		X
CD33	X	X¹ NCT02724163	X¹ NCT05077423	X¹ NCT03971799
CD38	X¹ NCT03860844			X
CD44v6	X			X
CD47	X
CD56		X		X
CD70	X	X		X
CD74		X
CD117		X
CD123	X	X¹ NCT05320380	X	X¹ NCT04318678, NCT04678336
CD135 (FLT3)			X	X¹ NCT03904069
Mesothelin		X	X	X
Folate receptor α (FOLR1)		X²		X
PRAME				X³
WT1				X³
HA-1				X^1,3 NCT03326921
NKG2DL				X
IL1RAP				X
CLL-1 (CLEC12A)		X	X	X

Indicates active pediatric trial with National Clinical Trials Network identifier provided.

Additional agent as C'dot drug conjugate.

T-cell receptor T cell.